Ryvu Therapeutics SA (PL:RVU)
:RVU
Top Page
Ryvu Therapeutics SA
(RVU)
Select Model
Select Model
Rating:44Neutral
Price Target:
zł28.00
▲(1.27% Upside)
Action:N/ADate:09/14/25
Ryvu Therapeutics SA's overall stock score of 44 reflects significant financial challenges as the primary concern, with persistent losses, negative cash flows, and rising leverage outweighing revenue growth. Valuation concerns due to a negative P/E ratio further dampen the outlook, while limited technical data provides no strong counterbalance.
Ryvu Therapeutics SA (RVU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
zł532.92M
Dividend YieldN/A
Average Volume (3M)26.70K
Price to Earnings (P/E)―
Beta (1Y)1.00
Revenue Growth15.45%
EPS Growth-25.81%
CountryPL
Employees328
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.76
Shares Outstanding23,120,148
10 Day Avg. Volume24,770
30 Day Avg. Volume26,695
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)11.64
Price to Sales (P/S)10.06
P/FCF Ratio-5.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.29
Revenue Forecast (FY)zł188.28M
Ryvu Therapeutics SA Business Overview & Revenue Model
Company Description
Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematol...
How the Company Makes Money
Ryvu Therapeutics generates revenue primarily through the development and commercialization of its drug candidates. The company earns money through various streams including milestone payments from partnerships with larger pharmaceutical companies...
Ryvu Therapeutics SA Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
55
Neutral
Cash Flow
25
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 62.25M | 77.97M | 46.86M | 38.80M | 11.19M |
| Gross Profit | -117.03M | 58.39M | 29.31M | 21.40M | -2.54M |
| EBITDA | -112.71M | -96.83M | -81.04M | -65.21M | -65.96M |
| Net Income | -101.23M | -111.44M | -92.11M | -83.78M | -79.08M |
Balance Sheet | |||||
| Total Assets | 224.44M | 378.78M | 403.20M | 474.98M | 228.81M |
| Cash, Cash Equivalents and Short-Term Investments | 107.68M | 225.40M | 233.67M | 102.44M | 88.23M |
| Total Debt | 71.72M | 75.51M | 906.00K | 2.77M | 5.07M |
| Total Liabilities | 153.69M | 234.89M | 143.61M | 131.59M | 59.39M |
| Stockholders Equity | 53.83M | 143.88M | 259.59M | 343.39M | 161.30M |
Cash Flow | |||||
| Free Cash Flow | -117.75M | -135.38M | -88.11M | 12.03M | -69.85M |
| Operating Cash Flow | -110.28M | -129.48M | -84.55M | 21.32M | -57.87M |
| Investing Cash Flow | 13.35M | 137.16M | -195.54M | 690.00K | 8.06M |
| Financing Cash Flow | -3.05M | 94.21M | 240.83M | -2.46M | -3.17M |
Ryvu Therapeutics SA Technical Analysis
Neutral
27.65
Price Trends
24.31
Negative
25.61
Negative
26.83
Negative
Market Momentum
-0.39
Negative
47.82
Neutral
78.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PL:RVU, the sentiment is Neutral. The current price of 27.65 is above the 20-day moving average (MA) of 22.57, above the 50-day MA of 24.31, and above the 200-day MA of 26.83, indicating a neutral trend. The MACD of -0.39 indicates Negative momentum. The RSI at 47.82 is Neutral, neither overbought nor oversold. The STOCH value of 78.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PL:RVU.
Ryvu Therapeutics SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | zł135.44M | -3.23 | -59.73% | ― | -74.16% | -192.42% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | zł569.02M | 975.15 | -1.25% | ― | 14.10% | -99.00% | |
44 Neutral | zł532.92M | -6.19 | -110.42% | ― | 15.45% | -25.81% | |
42 Neutral | zł446.49M | -4.87 | -109.96% | ― | -40.45% | 27.53% |
* Healthcare Sector Average
PL:RVU
Ryvu Therapeutics SA
23.05
-2.25
-8.89%
PL:SVE
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.
3.62
-0.84
-18.92%
PL:CTX
Captor Therapeutics SA
80.40
47.40
143.64%
PL:MOC
OncoArendi Therapeutics SA
5.38
-2.60
-32.58%
PL:SLV
Selvita SA
31.00
0.30
0.98%
PL:MAB
Mabion SA
8.38
-0.82
-8.91%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.